This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
IsoPlexis Corporation(NasdaqGS:ISO) dropped from S&P TMI Index CI
Berkeley Lights Closes IsoPlexis Merger; Combined Company PhenomeX to Begin Trading on Nasdaq Wednesday MT
IsoPlexis Corporation(NasdaqGM:ISO) dropped from NASDAQ Composite Index CI
Berkeley Lights, Inc. completed the acquisition of IsoPlexis Corporation from a group of shareholders. CI
Transcript : IsoPlexis Corporation - Shareholder/Analyst Call
IsoPlexis Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
IsoPlexis Corporation Auditor Raises 'Going Concern' Doubt CI
IsoPlexis Reports Lower Preliminary 2022 Revenue; Shares Down After-Hours MT
IsoPlexis Corporation Provides Preliminary Revenue Guidance for the Full Year Ended December 31, 2022 CI
Morgan Stanley Adjusts Price Target on IsoPlexis to $1.70 From $5, Maintains Equalweight Rating MT
Sector Update: Healthcare Stocks Finish Narrowly LowerThursday MT
Sector Update: Health Care Stocks Resisting Worst of Thursday Slide MT
SVB Leerink Adjusts Price Target on IsoPlexis to $1.50 From $2, Maintains Market Perform Rating MT
Top Premarket Gainers MT
North American Morning Briefing : Stock Futures Lower as Activity Winds Down DJ
Stocks to Watch : IsoPlexis, Lexicon Pharma, Micron Tech, Berkeley Lights DJ
Transcript : Berkeley Lights, Inc., IsoPlexis Corporation - M&A Call
Berkeley Lights to Acquire IsoPlexis for $57.8 Million in Stock MT
Berkeley Lights, Inc. announced a definitive agreement to acquire IsoPlexis Corporation from a group of shareholders for $56.3 million. CI
SVB Securities Adjusts Price Target on IsoPlexis to $2.50 From $3, Maintains Market Perform Rating MT
Transcript : IsoPlexis Corporation, Q3 2022 Earnings Call, Nov 10, 2022
Earnings Flash (ISO) ISOPLEXIS CORPORATION Reports Q3 Revenue $4.5M, vs. Street Est of $4.6M MT
IsoPlexis Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
IsoPlexis Corporation Provides Revenue Guidance for the Year 2022 CI
IsoPlexis Corporation Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform CI
Chart IsoPlexis Corporation
More charts
IsoPlexis Corporation is a life sciences company. The Company is engaged in building solutions to develop curative medicines and personalized therapeutics. The Company's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The Company's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company's IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.
More about the company
  1. Stock Market
  2. Equities
  3. ISO Stock
  4. News IsoPlexis Corporation
  5. Evercore ISI Starts IsoPlexis at Outperform With $24 Price Target